ネクセラファーマ株式会社 (4565.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenJPY 1,269.00

From 52W high−2.54%

Volume1.80M

Market capJPY 114.35B

P/E (TTM)—

P/S (TTM)3.4x

Div yield—

Key dataSep 18, 2026

Open

JPY 1,269.00

From 52W high

−2.54%

Volume

1.80M

Market cap

JPY 114.35B

ValuationView details →

P/E (Fwd)

15.7x

EV/EBITDA

68.5x

P/E (TTM)

—

RSI (14)

67.7

MomentumView details →

1D Return

+5.94%

YTD Return

+57.07%

ValuationView details →

P/E (Fwd)

15.7x

P/E (TTM)

—

EV/EBITDA

68.5x

EV/Sales

4.5x

P/S (TTM)

3.4x

P/B (TTM)

1.8x

ProfitabilityView details →

Gross Margin

62.58%

Net Margin

−29.15%

EBITDA Margin

−11.97%

ROE (TTM)

−15.67%

ROA (TTM)

−7.48%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+10.88%

EPS YoY

—

FCF YoY

−1.62%

Revenue CAGR 3Y

+23.90%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+5.94%

YTD Return

+57.07%

1Y Return

+26.98%

RSI (14)

67.7

vs 50D SMA

+24.84%

vs 200D SMA

+35.29%

Capital & dividendView details →

Debt/Equity

0.31x

Current Ratio

2.61x

Quick Ratio

1.86x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

34.23B

Net Income (TTM)

−9.98B

Op. CF (TTM)

−4.93B

Next earningsNov 6, 2026 →

Latest newsMore news →

Nexera Pharma shares surged sharply on September 8, 2026, following an analyst upgrade.13d ago

Nexera Pharma announced it will receive a milestone payment of $8.6 million from Centessa Pharmaceuticals, a subsidiary of Eli Lilly, due to progress in late-stage development of an OX2R agonist.17d ago

Similar companies

Mochida Pharmaceutical Co.,Ltd.4534.T PeptiDream Inc.4587.T ZERIA PHARMACEUTICAL CO.,LTD.4559.T KAKEN PHARMACEUTICAL CO.,LTD.4521.T GNI Group Ltd.2160.T Oncolys BioPharma Inc.4588.T Find similar companies →

Latest newsMore news →

Nexera Pharma shares surged sharply on September 8, 2026, following an analyst upgrade.13d ago Nexera Pharma announced it will receive a milestone payment of $8.6 million from Centessa Pharmaceuticals, a subsidiary of Eli Lilly, due to progress in late-stage development of an OX2R agonist.17d ago Neurocrine Biosciences' IND for NBI-1117567 Phase 2 trial in Alzheimer's cognitive impairment was accepted by the US FDA, triggering a $10 million milestone payment to Nexera Pharma.25d ago